
    
      The total study duration was 24 weeks which included a screening period of 4 weeks, a
      treatment period of 16 weeks, and a follow-up period of up to 4 weeks. Participants who
      completed the Week 16 visit were proposed to be enrolled in a long-term extension safety and
      efficacy study to assess safety, tolerability and efficacy of SAR442168.
    
  